APOA4 and adenoma: To validate APOA4 and FLNA as potential biomarkers, we conducted an independent validation study in cohort 3 (Figure 5A; Supplementary Table S4), including 37 healthy controls (H), 38 inflammatory polyp patients (A), and 45 adenoma patients (B).